Jobs / United States / Glaxosmithkline LLC
Early Development Leader (Oncology R & D)
Glaxosmithkline LLC · 🇺🇸 USA - Pennsylvania - Upper Providence
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles2 certified filings for “Statistics Leader” (Statisticians) in PA: $128k–$140k, median $134k. Most were filed at wage level I (50%) — 1 lottery entry, ≈15% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge. The location of this role will therefore subsequently change to Cambridge in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029. Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Find out more: Our approach to R&D Job Purpose As the Early Development Leader (EDL), you will lead the early development of oncology medicines from candidate selection through proof of concept. As the single point of accountability for your asset, you will set a clear strategy, make evidence-based go/no-go decisions, and partner with teams across research, clinical development, medical, regulatory, and commercial functions. We value scientific curiosity, decisive leadership, strong collaboration, and an unwavering focus on patient impact. This role offers significant growth potential and visible influence across the pipeline. Key Responsibilities This role will provide you with the opportunity to lead high-impact activities including: • Own the early development strategy and serve as the single point of accountability for one or more oncology assets, from candidate selection through proof of concept. • Define and drive translational and clinical plans — including experimental medicine studies and biomarker strategies — that support robust go/no-go decisions. • Identify key inflection points and make clear, evidence-based decisions to advance or stop programs. • Lead cross-functional teams, building alignment across clinical, medical, regulatory, manufacturing, and commercial partners. • Engage with external scientific, clinical, and regulatory communities to generate insights that sharpen development plans. • Proactively identify regulatory and operational risks, putting mitigation plans in place to keep programs on track. Team and Environment You will join a collaborative, matrixed R&D environment that bridges discovery science and clinical development. Working alongside multidisciplinary colleagues and external partners, you will design and deliver robust early development programs. We encourage open scientific discussion and practical problem-solving that accelerates development while upholding the highest scientific standards. Basic Qualifications We're looking for professionals who bring: • An advanced scientific or medical degree (MD, PhD, PharmD, or equivalent), or a relevant bachelor's degree paired with substantial oncology development experience. • Proven experience in early-stage oncology drug development, including translational medicine and experimental medicine design. • A demonstrated ability to translate preclinical data into actionable clinical development plans. • Experience leading cross-functional teams in a matrix environment and driving decisions across diverse stakeholders. • A track record of evidence-based go/no-go decision-making and defining clear development inflection points. • Strong communication skills, with the ability to present complex scientifi